Last Updated : March 27, 2025
Details
Generic Name:
inebilizumab
Project Status:
Pending
Therapeutic Area:
Immunoglobulin G4-related disease
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Uplizna
Project Line:
Reimbursement Review
Project Number:
SR0889-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of
Immunoglobulin G4-related disease (IgG4-RD) in adult patients.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of
Immunoglobulin G4-related disease (IgG4-RD) in adult patients.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : March 27, 2025